相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
Timothy R. Wilson et al.
MOLECULAR CANCER RESEARCH (2019)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim et al.
LANCET ONCOLOGY (2017)
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
Timothy R. Wilson et al.
NPJ BREAST CANCER (2016)
Clinical implications of molecular heterogeneity in triple negative breast cancer
Brian D. Lehmann et al.
BREAST (2015)
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Management of breast cancer with targeted agents: importance of heterogenicity
Serena Di Cosimo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)